EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer

Kunihiro Odagiri, Yoshihiko Tasaki, Taku Naiki iD, Toshiharu Morikawa iD, Keitaro Iida, Yusuke Noda, Rika Banno, Teruki Isobe, Nobuhiko Shimizu, Maria Aoki, Yoshihisa Mimura iD, Yosuke Sugiyama iD und 7 weitere

Cancer Medicine · 2026-07 · 15 (7)

DOI: 10.1002/cam4.72072 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 01.07.2026. Verfasst von Kunihiro Odagiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions, Eosinophils. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an unmet need to predict immune‐related adverse events (irAEs) in patients receiving immune checkpoint inhibitors. This study aimed to examine whether eosinophils can predict irAEs in metastatic urothelial carcinoma (mUC). In this multicenter cohort study, we retrospectively examined eosinophil before (baseline sample) and 3 weeks after treatment (3‐week sample) in 124 patients with mUC treated with pembrolizumab between January 2018 and October 2024. We divided the patients into two groups depending on whether they had experienced an irAE (irAE group) or not (non‐irAE group). The variation in eosinophil proportion from baseline to 3 weeks was significantly higher in the irAE group than in the non‐irAE group (non‐irAE, 2.4%–3.1%; irAE, 2.2%–4.3%; p < 0.05). Notably, the variation in eosinophils from baseline to 3 weeks in patients with bladder cancer was significantly higher in the irAE group than in the non‐irAE group (non‐irAE, 2.5%–2.8%; irAE, 1.9%–4.1%; p < 0.05), but not in upper urinary tract urothelial cancer (non‐irAE, 2.2%–3.7%; irAE, 2.8%–4.4%; p = 0.97). The optimal cutoff value for eosinophils in patients with bladder cancer against the occurrence of any‐grade irAEs was 5.0% (area under the curve = 0.655). Multivariable analyses showed that eosinophil levels ≥ 5.0% increased the risk of any‐grade irAEs in patients with bladder cancer (odds ratio 3.61, 95% confidence interval, 1.00–13.0). An eosinophil proportion ≥ 5.0% may be an effective biomarker for evaluating pembrolizumab‐induced irAEs in patients with mUC, particularly those with bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsEosinophilsImmune Checkpoint InhibitorsUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective Studies

Stichwörter der Autor:innen

bladder cancereosinophilimmune‐related adverse eventpembrolizumaburothelial carcinoma

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitorspembrolizumab

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Urology, Nagoya City University West Medical Center, Nagoya, Japan.
  • Department of Urology, Anjo Kosei Hospital, Anjo, Japan.
  • Department of Urology, Konan Kosei Hospital, Konan, Japan.

ORCID-Profile: Taku Naiki, Toshiharu Morikawa, Yoshihisa Mimura, Yosuke Sugiyama, Noriyasu Kawai, Yoko Furukawa-Hibi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Odagiri, K., Tasaki, Y., Naiki, T., Morikawa, T., Iida, K., Noda, Y., Banno, R., Isobe, T., Shimizu, N., Aoki, M., Mimura, Y., Sugiyama, Y., Nagai, T., Etani, T., Hamamoto, S., Ando, R., Kawai, N., Furukawa-Hibi, Y., & Yasui, T. (2026). Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72072

Vancouver

Odagiri K, Tasaki Y, Naiki T, Morikawa T, Iida K, Noda Y, et al. Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72072

BibTeX
@article{Odagiri2026,
  author = {Odagiri, Kunihiro and Tasaki, Yoshihiko and Naiki, Taku and Morikawa, Toshiharu and Iida, Keitaro and Noda, Yusuke and Banno, Rika and Isobe, Teruki and Shimizu, Nobuhiko and Aoki, Maria and Mimura, Yoshihisa and Sugiyama, Yosuke and Nagai, Takashi and Etani, Toshiki and Hamamoto, Shuzo and Ando, Ryosuke and Kawai, Noriyasu and Furukawa-Hibi, Yoko and Yasui, Takahiro},
  title = {Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune‐Related Adverse Events in Patients With Bladder Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cam4.72072}
}
Kostenlos starten →